ADC Therapeutics SA (ADCT) Stock
NYSE · ADCT
Key stats
- Market cap
- $225.06M
- Price / Earnings ratio
- -2.6x
- EPS (TTM)
- -$0.46
- Volume
- Loading
- 52-week high
- $4.98
- 52-week low
- $0.78
Source: third-party data provider, as of November 13, 2026
Compare with ADCT
Recent news

MarketBeat
ADC Therapeutics Q2 Earnings Call Highlights
ADCTAugust 13, 2026
MarketBeat
ADC Therapeutics Q2 Earnings Call Highlights
ADCT

Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADCTAugust 13, 2026
Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADCT

Zacks Investment Research
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADCTJune 4, 2026
Zacks Investment Research
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADCT

Reuters
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADCTJune 4, 2026
Reuters
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADCT
Technical indicators
- RSI 14
- 53.80
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- 0.07
- MACD histogram
- -0.01
- SMA 50
- $1.39
- Price above SMA 50
- EMA 50
- $1.45
- Price above EMA 50
- SMA 200
- $2.40
- Price below SMA 200
- EMA 200
- $2.37
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Strong Sell0
Sell0
Hold0
Buy1
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
252M166M83M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
742M489M245M0
Revenue to Profit
2025$81.4M
Revenue$0.0
Cost of revenue$75.6M
Gross profit$0.0
Operating expenses$-142.6M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
ADC Therapeutics Q2 Earnings Call Highlights
ADCTAugust 13, 2026
MarketBeat
ADC Therapeutics Q2 Earnings Call Highlights
ADCT

Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADCTAugust 13, 2026
Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADCT

Zacks Investment Research
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADCTJune 4, 2026
Zacks Investment Research
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADCT

Reuters
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADCTJune 4, 2026
Reuters
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADCT

24/7 Wall Street
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
ADCTMay 14, 2026
24/7 Wall Street
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
ADCT

Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADCTMay 4, 2026
Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADCT

Zacks Investment Research
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ADCTMay 1, 2026
Zacks Investment Research
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ADCT

Zacks Investment Research
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
ADCTApril 15, 2026
Zacks Investment Research
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
ADCT

Zacks Investment Research
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
ADCTMarch 13, 2026
Zacks Investment Research
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
ADCT

Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADCTMarch 10, 2026
Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADCT
About ADC Therapeutics SA
No description available.
SectorHealthcare
IndustryBiotechnology
Employees188
CEODr. Ameet Mallik M.B.A., M.S.
IPO DateMay 15, 2020
HeadquartersEpalinges, Switzerland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ameet Mallik M.B.A., M.S. | CEO & Director | 1973 |
| Mr. Jose I. Carmona M.B.A. | Chief Financial Officer | 1972 |
| Dr. Mohamed Zaki M.D., Ph.D. | Chief Medical Officer | 1965 |
| Ms. Lisa Michelle Kallebo | Corporate Controller & Chief Accounting Officer | — |
| Dr. David S. Ege Ph.D. | Chief Technical Officer | 1974 |
| Ms. Nicole Riley | Head of Investor Relations & Corporate Communications | — |
| Mr. Peter J. Graham Esq. | Secretary and Chief Legal & Compliance Officer | 1967 |
| Ms. Kimberly Pope | Senior VP & Chief People Officer | 1967 |
| Ms. Kristen Harrington-Smith | Chief Commercial Officer | 1973 |
| Ms. Marcy Graham | Investor Relations Officer | 1967 |
Fundamentals
Valuation
Price-to-sales ratio2.50
Price-to-book value-0.85
Profitability
Return on Equity45.00%
Return on Assets-33.00%
Return on Sales-57.00%
Gross margin (latest quarter)90.88%
EBITDA$-44.94M
Trading
Average volume1,413,094
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 53.80
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- 0.07
- MACD histogram
- -0.01
- SMA 50
- $1.39
- Price above SMA 50
- EMA 50
- $1.45
- Price above EMA 50
- SMA 200
- $2.40
- Price below SMA 200
- EMA 200
- $2.37
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $5.00
- Average
- $5.00
- High
- $5.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.3 | -7.6 | ||||||||||
| 2022 | -19.3 | +0.3 | -11.3 | -20.6 | -42.6 | +21.4 | -13.2 | -3.4 | -28.9 | -8.1 | -17.2 | +10.3 |
| 2023 | +42.3 | -33.9 | -42.3 | -5.4 | +19.9 | -9.7 | -31.2 | -20.5 | -26.2 | -14.6 | +23.9 | +49.5 |
| 2024 | +84.6 | +34.2 | -7.6 | -0.7 | -27.2 | -4.5 | -9.8 | -5.2 | +15.4 | -9.6 | -18.0 | -14.2 |
| 2025 | -16.0 | +11.4 | -11.3 | +5.9 | +116.1 | -23.6 | +3.7 | +14.1 | +29.0 | +11.5 | +2.9 | -16.7 |
| 2026 | +2.6 | +5.1 | -10.3 | -0.5 | -11.2 | -68.5 | -7.9 | +11.4 | -1.6 | +41.7 | +3.9 |
Compare stocks
Market cap
$225.06M
-
-
-
Price / Earnings ratio
-2.60
-
-
-
Price / Sales ratio
2.50
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,413,094
-
-
-
Earnings per share
$-0.46
-
-
-



